Effectiveness of inhaled furosemide for acute asthma exacerbation: a meta-analysis

Table 2 Trial results

	Furosemide								Placebo
	PEFR				FEV1.0				PEFR				FEV 1.0
Study (year)	Baseline airflow	SD	Post-treatment airflow	SD	Baseline airflow	SD	Post-treatment airflow	SD	Baseline airflow	SD	Post-treatment airflow	SD	Baseline airflow	SD	Post-treatment airflow	SD
Alshehri and colleagues, 2005 [5]	59.0	22.0	84.9	14.0	58.5	14.5	80.2	13.9	57.2	25.4	80.7	17.4	56.7	17.3	77.8	19.1
Nuhoğlu and colleagues, 2006 [3]	178	65.9	222	66.1	N/A	N/A	183	51.7	218	60.3	N/A	N/A
	Baseline airflow	SD	Net airflow improvement above baseline	SD	Baseline airflow	SD	Net airflow improvement above baseline	SD	Baseline airflow	SD	Net airflow improvement above baseline	SD	Baseline airflow	SD	Net airflow improvement above baseline	SD
González-Sánchez and colleagues, 2002 [4]	N/A	N/A	0.820	0.460	0.910	0.067	N/A	N/A	0.850	0.340	0.980	0.078
Nannini and colleagues, 1992 [1]	147	68.0	269	89.7	N/A	N/A	234	82.0	316	56.2	N/A	N/A
Ono and colleagues, 1997 [6]	171	20.0	205	45.1	1.18	0.13		178	25.0	198	21.3	1.32	0.74	N/A
Pendino and colleagues, 1998 [2]	200	71.0	426	98.0	N/A	N/A	209	68.0	337	73.2	N/A	N/A

FEV1.0, forced expiratory volume in 1 second; N/A, not available; PEFR, peak expiratory flow rate; SD, standard deviation.

ISSN: 1364-8535